Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Human T cell lymphotropic virus types I and II in intravenous drug users in San Francisco: risk factors associated with seropositivity.

Feigal E, Murphy E, Vranizan K, Bacchetti P, Chaisson R, Drummond JE, Blattner W, McGrath M, Greenspan J, Moss A.

J Infect Dis. 1991 Jul;164(1):36-42.

PMID:
2056217
2.

Human T lymphotropic virus type II (HTLV-II) infection in a cohort of New York intravenous drug users: an old infection?

Khabbaz RF, Hartel D, Lairmore M, Horsburgh CR, Schoenbaum EE, Roberts B, Hartley TM, Friedland G.

J Infect Dis. 1991 Feb;163(2):252-6.

PMID:
1988509
3.

HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates.

de la Fuente L, Toro C, Soriano V, Brugal MT, Vallejo F, Barrio G, Jiménez V, Silva T; Project Itínere Working Group.

J Clin Virol. 2006 Mar;35(3):244-9. Epub 2005 Sep 6.

PMID:
16143565
4.

Prevalence and risk factors for HTLV-II infection in 913 injecting drug users in Stockholm, 1994.

Krook A, Albert J, Andersson S, Biberfeld G, Blomberg J, Eklund I, Engström A, Julander I, Käll K, Martin C, Stendahl P, Struve J, Sönnerborg A.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 15;15(5):381-6.

PMID:
9342259
5.

Prevalence of human T cell lymphotropic virus types 1 and 2 (HTLV-1/2) in selected Tijuana subpopulations.

Guerena-Burgueno F, Benenson AS, Sepulveda-Amor J, Ascher MS, Vugia DJ, Gallo D.

Am J Trop Med Hyg. 1992 Aug;47(2):127-32.

PMID:
1503181
6.

HTLV-I and HTLV-II infections among HIV-1 seropositive patients in Sao Paulo, Brazil.

de Araujo AC, Casseb JS, Neitzert E, de Souza ML, Mammano F, Del Mistro A, De Rossi A, Chieco-Bianchi L.

Eur J Epidemiol. 1994 Apr;10(2):165-71.

PMID:
7813694
7.

Seroepidemiology of human T-cell lymphotropic virus type I/II in northeastern Brazil.

Moreira ED Jr, Ribeiro TT, Swanson P, Sampaio Filho C, Melo A, Brites C, Badaró R, Toedter G, Lee H, Harrington W Jr.

J Acquir Immune Defic Syndr. 1993 Aug;6(8):959-63.

PMID:
8315579
8.

Infection with human T lymphotropic virus types I and II in sexually transmitted disease clinics in Baltimore and New Orleans.

Wiktor SZ, Cannon RO, Atkinson WL, Lutz B, Hook EW 3rd, Blattner WA, Quinn TC.

J Infect Dis. 1992 May;165(5):920-4.

PMID:
1569344
9.

Seroprevalence of HTLV-I and HTLV-II among a cohort of HIV-infected women and women at risk for HIV infection. Women's Interagency HIV Study.

Telzak EE, Hershow R, Kalish LA, Hardy WD Jr, Zuckerman E, Levine A, Delapenha R, DeHovitz J, Greenblatt RM, Anastos K.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):513-8.

PMID:
9859966
10.

Incidence and risk factors for human T-lymphotropic virus type II seroconversion among injecting drug users in Baltimore, Maryland, U.S.A.

Vlahov D, Khabbaz RF, Cohn S, Galai N, Taylor E, Kaplan JE.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 May 1;9(1):89-96.

PMID:
7712239
11.

Low prevalence of human T-cell leukaemia virus-I and -II infection among drug users in Amsterdam, The Netherlands.

van den Hoek JA, Al EJ, Huisman JG, Goudsmit J, Coutinho RA.

J Med Virol. 1991 Jun;34(2):100-3.

PMID:
1890409
12.

Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA.

Lee HH, Weiss SH, Brown LS, Mildvan D, Shorty V, Saravolatz L, Chu A, Ginzburg HM, Markowitz N, Des Jarlais DC, et al.

J Infect Dis. 1990 Aug;162(2):347-52.

PMID:
2373871
13.

Prevalence and epidemiologic correlates of human T cell lymphotropic virus infection among intravenous drug users.

Schwebke J, Calsyn D, Shriver K, Saxon A, Kleyn J, Oluoch-Mitchell E, Olmstead L, Fisher LD, Krone M, Ashley R, et al.

J Infect Dis. 1994 May;169(5):962-7.

PMID:
8169427
14.

HTLV-I and -II in intravenous drug users from Sweden and Denmark.

Blomberg J, Moestrup T, Frimand J, Hansson BG, Krogsgaard K, Grillner L, Nordenfelt E.

Scand J Infect Dis. 1994;26(1):23-6.

PMID:
8191236
15.

HTLV-1 and HTLV-2 infections in HIV-infected individuals from Santos, Brazil: seroprevalence and risk factors.

Etzel A, Shibata GY, Rozman M, Jorge ML, Damas CD, Segurado AA.

J Acquir Immune Defic Syndr. 2001 Feb 1;26(2):185-90.

PMID:
11242188
16.
17.

Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA.

Khabbaz RF, Douglas JM Jr, Judson FN, Spiegel RA, St Louis ME, Whittington W, Hartley TM, Lairmore M, Kaplan JE.

J Infect Dis. 1990 Jul;162(1):241-4.

PMID:
2192006
18.

HTLV infections among Swedish intravenous drug users in 1992.

Andersson S, Krook A, Käll K, Julander I, Thorstensson R, Biberfeld G.

Scand J Infect Dis. 1995;27(6):547-50.

PMID:
8685631
19.

Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States.

Murphy EL, Watanabe K, Nass CC, Ownby H, Williams A, Nemo G.

J Infect Dis. 1999 Dec;180(6):1777-83.

20.

Human T-lymphotropic virus type II seroprevalence among emergency department and clinic patients.

Agranoff D, Varney K, Khayam-Bashi H, Murphy EL.

West J Med. 1996 Jun;164(6):481-5.

Items per page

Supplemental Content

Write to the Help Desk